Mercia Technologies Plc, which provides seed and follow-on funding to UK technology companies, has expanded the geographical penetration of its operations with the acquisition of Enterprise Ventures Group Ltd, a company located in the north of England.
GlaxoSmithKline Plc has signed an agreement with a service company in Germany to gain access to technology for industrialising cell and gene therapies. The two parties will also discover new chimeric antigen-receptor T (CAR T) cell therapies.
eTheRNA immunotherapies NV, a 2013 spinout from the Free University of Brussels, has raised €24 million in a Series A equity financing for the development of its TriMix-based immunotherapy for treating melanoma, breast cancer and infectious diseases.
Nanobiotix SA, a developer of X-ray enhancement products, has raised €21.3 million with a private equity placement to finance the further development of its lead product NBTXR3 for the treatment of soft tissue sarcoma and a number of other cancers.
Cambridge Epigenetix Ltd has raised $21 million in a Series B equity financing for the further development of its epigenetic tools for analysing the DNA methylome. Prominent financers from California, US provided the bulk of the funding.
BerGenBio AS, a privately-held Norwegian company, has raised NOK212 million (€22.4 million) in new equity to advance the clinical development of its lead product BGB324 for the treatment of acute myeloid leukaemia (AML) and non-small cell lung cancer.
After achieving financial stability and the successful launch of its lead asthma product flutiform, the board of Skyepharma Plc has agreed to merge with Vectura Group Plc, another developer of respiratory products.
Aprea AB has raised €46 million in a Series B equity financing co-led by Versant Ventures and 5AM Ventures. The privately-held Swedish company is developing a small molecule drug that reactivates a tumour suppressor protein known as p53.
Scancell Holdings Plc is planning to raise £6.8 million in a two-part equity offering to finance further development of its anti-cancer vaccines. The UK company, which is listed on the AIM market of the London Stock Exchange, has made arrangements to place £3 million of its shares with institutions.
Autolus Ltd, a spin-out from University College London (UCL) that is developing engineered T cell therapies for cancer, has raised £40 million in a Series B financing round bringing total commitments to date from private investors to £70 million.